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The  cattle  tick,  Rhipicephalus  microplus,  is  regarded  as the  most  economically  important  ectoparasite  of
livestock  globally.  Control  is achieved  primarily  through  the  use  of  acaricides.  This  approach  is  hampered
by  the  development  of  resistance  to  commercial  acaricides  among  cattle  tick  populations.  Vaccination
against  R.  microplus  infestation  is  another  technology  that  can be  integrated  for  effective  cattle  tick  control.
Proteins  belonging  to the  Kunitz-BPTI  family  are  abundant  in  cattle  tick  salivary  glands,  midgut,  and
ovaries.  These  organs  are  attractive  targets  for the  development  of  a novel  cattle  tick vaccine.  Efﬁcacy
assessment  against  cattle  tick  infestation  in  bovines  using  a  vaccine  containing  the  recombinant  form  of a
member  of  the Kunitz  family  from  R.  microplus  produced  in  a  yeast  expression  system  is  reported  for  the
ﬁrst  time  here.  The  yeast  Pichia  pastoris  was  bioengineered  to  produce  the  recombinant  version  of  a  trypsinaccination
rypsin inhibitor
ecombinant protein
inhibitor  that  is expressed  in cattle  tick larvae  (rRmLTI).  Immunization  with  rRmLTI  afforded  32%  efﬁcacy
against  R.  microplus.  The  estimated  molecular  weight  of rRmLTI  was  46  kDa.  Structural  homology  to  the
native  form  of  the  larval  trypsin  inhibitor  was  documented  by  recognition  of  rRmLTI  in  Western-blots
using  polyclonal  antibodies  from  mice  immunized  with  cattle  tick  larval  extract  or  rRmLTI.  Bioinformatics
analysis  of  the  partial  nucleotide  and deduced  amino  acid  sequences  indicated  that  the  rRmLTI  closely
resembles  BmTI-6,  which  is a  three-headed  Kunitz  protein  present  in  cattle  tick ovary  and  fat  tissue.. Introduction
Ectoparasitism of cattle by the southern cattle tick, Rhipicephalus
icroplus, inﬂicts severe economic losses to the livestock industry.
attle productivity is undermined by the direct effects of ectopar-
sitism and indirectly by the role R. microplus plays as vector of
he infectious agents causing bovine babesiosis and anaplasmo-
is [1,2]. The control of R. microplus is achieved mainly through
he use of chemical acaricides [3]. However, chemical acaricides
ave not been utilized judiciously. This has led to the develop-
ent of acaricide resistance among populations of R. microplus4,5].
Vaccinating cattle with tick molecules formulated as antigens to
licit a protective immune response is a strategy proven useful for
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Open access under the Elsevier OA license.Published by Elsevier Ltd.
the integrated control of cattle ticks [7,10,36]. The beneﬁts of using
anti-tick vaccines as part of an integrated control program include a
reduction in the use of acaricides, extending the useful life of acari-
cides by delaying the onset of resistance, reducing the incidence of
R. microplus-borne diseases, and decreased production costs [6,8,9].
The only tick molecule currently developed and marketed as a com-
ponent of an anti-tick vaccine is Bm86 from R. microplus. Bm86 is a
glycoprotein expressed in eggs a few days after oviposition, unfed
and blood-fed larvae, nymphs, adult males, and in the ovaries of
partially engorged adult females [11]. The Bm86 gene appeared to
be down-regulated in the ovaries of ticks feeding on cattle infected
with B. bovis [12]. Anti-tick vaccine products based on the recom-
binant version of Bm86 (rBm86) were registered in Australia under
the trade name TickGARD®, and in Cuba as Gavac® in the 1990s
[13,36]. The rBm86-based vaccines are highly efﬁcacious against
R. annulatus [38,39], but the level of efﬁcacy against R. microplus
varies according to characteristics of the tick population targeted
Open access under the Elsevier OA license.and host factors among other things [14,15]. Pen trials conducted
in the state of Mato Grosso do Sul, Brazil revealed that the efﬁ-
cacy of Bm86-based vaccines against the Campo Grande strain of
R. microplus ranged from 31 to 49% [17,18].
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Efﬁcacy around 99% against R. annulatus obtained with Bm86-
ased vaccines is an indication of the consistent high level of
nti-R. microplus immunoprotection that a novel antigenic and
mmunogenic tick molecule, or combinations thereof, could elicit
n vaccinated cattle. Such level of efﬁcacy offers the opportunity
o incorporate vaccination as a tool for the integrated eradication
f cattle fever tick populations [40,41]. The search for protective
ntigens that are highly efﬁcacious against R. microplus contin-
es. Proteinase inhibitors have received attention as a group of
olecules found in ticks with potential for use as immunogens in
n anti-tick vaccine. Several trypsin inhibitors that are present in
he egg, larval and adult stages of R. microplus have been described
19–21]. It has been suggested that the R. microplus serine protease
nhibitors may  be involved in larval attachment at the bite site and
lood feeding [22]. Trypsin inhibitors from R. microplus larvae puri-
ed in their native form elicited a protective immune response in
accinated cattle yielding 72.8% efﬁcacy, and 69.7% reduction in
he number of adult female ticks completing the parasitic phase of
heir life cycle [22]. However, a peptide designed from one of the
. microplus larval trypsin inhibitors afforded only 18.4% immuno-
rotection against tick infestation in crossbred cattle [23].
The  use of recombinant trypsin inhibitors can circumvent the
hallenge of having to purify trypsin inhibitors in sufﬁcient quan-
ities to conduct cattle tick vaccination tests [21,22]. An expressed
equence tag originally identiﬁed in R. microplus larvae was later
eported to correspond to sequence ampliﬁed from ovarian tissue
oding for the fragment of a Kunitz-BPTI domain protease inhibitor
ermed rBmTI-6 [21,24]. The rBmTI-6 was expressed in the Pichia
astoris system and characterized as a three-headed Kunitz-bovine
ancreatic trypsin inhibitor, but its ability to protect immunized
attle against tick infestation remained to be determined [21]. Here,
he partial nucleotide sequence of the putative R. microplus larval
rypsin inhibitor was used to produce the recombinant polypep-
ide in the yeast expression system to probe its immunoprotective
roperties [24]. Results of the cattle immunization trial and other
xperiments using the recombinant R. microplus larval trypsin
nhibitor (rRmLTI) are also reported.
. Materials and methods
.1.  Ticks
Ticks used for this study were obtained from a laboratory
olony maintained at EMBRAPA Beef Cattle. This colony was  estab-
ished using ticks collected from bovines in ranches around Campo
rande, Matto Grosso do Sul, Brazil. Ticks were maintained under
aboratory conditions for two years prior to use in the experiments
eported here. Cattle were used to cycle the tick progeny. Tick
tages requiring incubation were kept in the laboratory at 28 ◦C
nd 80% relative humidity. The Campo Grande cattle tick strain is
usceptible to commercially available acaricides.
.2. Transformation of Pichia pastoris with RmLTI DNA construct
nd  sequence analysis
The  expressed sequence tag (EST) coding for RmLTI (GenBank
D: CK186726 [21,24]) was optimized for P. pastoris codon usage,
nd synthesized by Epoch Biolabs, Inc. Codon optimization was
one using Epoch Biolabs, Inc. proprietary software set at 15% cut
ff for codon efﬁciency. This RmLTI DNA fragment was cloned into
PICZA, producing the pPICZRmLTI construct. The recombinant
lasmid codes for a His tag that is added to the N-terminus of the
rotein product. Previously described procedures were followed to
roduce rRmLTI in the P. pastoris expression system [25].0 (2012) 6678– 6685 6679
Alignment, similarity, and discordance comparisons based on
bioinformatics techniques were conducted between predicted
amino acid sequences for: rRmLTI, EST CK186726, BmTI-6 from
ovarian cDNA (GenBank ID: P83606.2), and N-terminal amino acid
sequence information for BmTI-A (GenBank ID: P83609), BmTI-D
(GenBank ID: P83607), BmTI-2 (GenBank ID: P83603), and BmTI-3
(GenBank ID: P83604). ClustalW from the BioEdit suite was used
with Vector NTI® software (Invitrogen) as described previously to
conduct the bioinformatics analyses [16]. The amino acid sequence
from rRmLTI was submitted to protein function and superfamily
analysis using the protein domains identiﬁer software InterProScan
[42].
2.3. rRmLTI quantitation and puriﬁcation, and murine antibody
production
Protein  concentration in P. pastoris culture supernatant was
quantiﬁed as described previously [25]. Proteins were precipitated
with methanol and the precipitated proteins resuspended in dena-
turing binding buffer (8 M Urea, 20 mM sodium phosphate pH 7.8,
500 mM  NaCl). The rRmLTI was  puriﬁed using a Ni2+ charged Ni-
NTA (Qiagen, Hilden, Germany) afﬁnity column with denaturing
elution buffer (8 M Urea, 20 mM Sodium Phosphate pH 4.0, 500 mM
NaCl) and the puriﬁcation process monitored by 7.5% SDS-PAGE.
Eluted fractions of high purity were pooled and dialyzed against
PBS.
Animal care and use was conducted at EMBRAPA Beef Cat-
tle according to institutional guidelines. Polyclonal serum against
R. microplus larval extract or rRmLTI was produced using BALB/c
mice as described previously [25]. The RmLTI vaccine was  prepared
with 500 g of rRmLTI protein resuspended in 4 mL  of 150-mM
Tris–HCl at pH 7.4 and emulsiﬁed with 6 mL of Montanide ISA 61
VG (Seppic, Paris). Twelve female BALB/c mice were used, which
were separated into two groups of six animals. One group received
the rRmLTI formulation and the other the larval extract prepa-
ration. Each mouse within the respective group was immunized
with 50 g mL−1 dose−1 of rRmLTI, or 100 g mL−1 dose−1 of larval
extract. Three subcutaneous doses were applied at 21-day intervals.
Sera were collected 21 days after the last dose.
2.4. rRmLTI electrophoresis and Western blotting
Electrophoresis analysis was  performed on material from a 10%
polyacrylamide gel run with 10 L of culture supernatant per well
containing 0.55 g L−1 of protein. Subsequent Western blotting
analysis was performed as previously described [25].
2.5.  Pen trial, bovine serum analysis, and efﬁcacy assessment
The  rRmLTI antigen expressed in P. pastoris was  adjuvated with
Montanide ISA 61 VG (Seppic, Paris) and doses of 2 mL containing
100 g of the recombinant protein prepared. One-year old Holstein
calves were randomly distributed into two groups of six animals
each. One group was immunized with rRmLTI antigen puriﬁed and
formulated as described above. The second group (negative con-
trols) was  injected with adjuvant/saline alone. Serum samples were
collected and processed, and all procedures involving ticks were
performed according to methods described previously [17]. Sera
obtained immediately before the initial injection, and at different
time points thereafter, from each of the six cattle in the vaccinated
and control groups were pooled and stored in an ultralow freezer
until ready for ELISA testing.
For  ELISA, microtiter plates were coated with 1 g mL−1 of
rRmLTI antigen in 20 mM  sodium carbonate buffer (pH 9.6), 50 L
per well, and incubated overnight at 4 ◦C. Duplicate samples of
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sig. 1. Identiﬁcation of P. pastoris product as larval trypsin inhibitor present in R. mi
.  pastoris transformed with pPICZA-RmLTI was processed to perform: (a) electro
BenchMarkTM Protein Ladder, Invitrogen]), and rRmLTI (supernatant of P. pastor
onoclonal antibody, (2) serum from mice vaccinated with rRmLTI, (3) serum from
ooled sera for each group and sampling date were tested. Sub-
equent procedures were performed as described previously [25].
Procedures described before were followed to assess treatment
ffects on tick biology and vaccine efﬁcacy [17,26]. Engorged female
icks dropping off of cattle from each group were collected daily for
3 days and incubated in the laboratory to obtain eggs that were
ooled until 1 gram was accumulated. The egg masses obtained per
ollection day from several ticks in each group were incubated to
etermine hatching rates.
.6.  Ex vivo feeding of anti-rRmLTI IgG and assessment of tick egg
closion  rates
Serum  samples from bovines immunized with rRmLTI were
ollected just prior to tick infestation and subjected to afﬁn-
ty chromatography on a protein A-Sepharose column to purify
mmunoglobulin G (IgG). The IgG eluted from the column resulted
n a yield of 5 mg  mL−1 of non-immune serum. Four groups, each
onsisting of ten adult female ticks, were set up for treatment. Each
ick in the respective group was fed with the antibody mixture
ontaining 0, 25, 50, or 100 g of puriﬁed IgG in 20 L by placing
 capillary tube in its hypostome. The effect on egg eclosion was
ssessed as described previously [17].
.7. Statistics
Data on female reproductive parameters were analyzed using
 t-test. Otherwise, differences between means were determined
sing one-way analysis of variance (ANOVA). Differences were con-
idered signiﬁcant when p < 0.05.
.  Results.1. Production of rRmLTI in P. pastoris expression system
Identity of the DNA insert in pPICZRmLTI was  conﬁrmed by
equencing and alignment with the RmLTI clone sequence. Ones larvae by electrophoresis and immunoblotting. Supernatant of culture containing
sis (SDS-PAGE 10%) where the gel was loaded with M (molecular weight marker
ure expressing rRmLTI); (b) Western blot of rRmLTI detected with: (1) anti-His
 vaccinated with larval extract, and (4) serum from unvaccinated mice.
Mut+ clone was selected and analysis of the induced recombinant
protein revealed a band of approximately 46 kDa. The calculated
molecular weight for rRmLTI was  37.9 kDa. It remains to be val-
idated if post-translational modiﬁcation through glycosylation,
potentially adding 8–9 mannose and two N-acetyl-glucosamine
molecules, may  have caused the discrepancy between the calcu-
lated and observed molecular weights of the protein product in P.
pastoris. Direct quantiﬁcation from culture supernatants revealed
rRmLTI production levels of 550 mg  L−1. Analysis of the nickel col-
umn puriﬁcation product showed a protein of 46 kDa and the yield
following puriﬁcation was 870 mg  L−1. Western blot analysis of
the rRmLTI protein was carried out with primary sera from mice
(anti-R. microplus larval extract and anti-rRmLTI) and anti-His tag
monoclonal antibody revealing afﬁnity for a protein of approxi-
mately 46 kDa (Fig. 1).
3.2. Immunoprotection against R. microplus infestation in cattle
vaccinated  with rRmLTI
The  antibody response of cattle immunized with the vaccine
formulation containing rRmLTI is shown in Fig. 2. Antibody levels
against rRmLTI peaked around 31 days after the second booster
immunization. Tick infestations were established around ten days
before the apparent decline in the speciﬁc antibody response com-
menced. A transient effect on the average weight of engorged adult
female ticks dropping off of vaccinated cattle was apparent through
the ninth day of the collection period (Fig. 3). With the exception of
days 2 and 4, the average weight of engorged female ticks collected
from the vaccinated group was  signiﬁcantly lower up to day nine
(Fig. 3; p < 0.05). Equivalence of the average engorged adult female
tick weight between groups beyond day 9 of the collection period
was temporally associated with the aforementioned decline in anti-
rRmLTI antibody levels (Fig. 2). A similar tendency was observed
in the eclosion rate for eggs collected from ticks detaching from
vaccinated cattle (Fig. 4).
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Table  1
Efﬁcacy of vaccine containing recombinant R. microplus larval trypsin inhibitor against ticks infesting cattle and its effect on female reproductive parameters.
Animal Tick total number Tick mean weight (mg) Egg mean weight (mg) Larval hatchability (%)
Control Vaccinated Control Vaccinated Control Vaccinated Control Vaccinated
1 1209 818 267 210 112 161 95 90
2  661 441 254 209 138 142 98 85
3 571 588 276 209 121 143  97 86
4 521 602  285 234 145 160 98 89
5 1089  671 304 209 160 154 96 91
6  543 89 275 190 149 125 96 87
Mean  ± SDa 766 ± 303 535 ± 250 277 ± 17 210 ± 14 138 ± 18 148 ± 014 97 ± 1.2 88 ± 2.4
t-Test  p = 0.1810 p < 0.0001 p = 0.3040 p < 0.0001
% Reductionb DT = 30.15 DW = 24.66 DO = −7.27 DF = 8.97
Efﬁcacy  = 100 [1 − (535/766 ×148/138 ×88/97)] = 32%
les are
: DT, 
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ca Arithmetic mean ± standard deviation; p-values of t-test for independent samp
b Percent reduction was calculated in relation to the control unvaccinated group
%) = 100 [l − (CRT × CR0 × CRF)]; where CRT: reduction in the number of adult fema
The cumulative count of engorged adult female ticks collected
p to day 13 after detachment started was used to calculate the
ffects of vaccination with rRmLTI (Table 1). Vaccinated cattle had
0% less ticks detaching from them than the animals injected with
djuvant only. Although egg laying capacity was unaffected, there
as a signiﬁcant effect associated with vaccination on tick weight
nd larval hatchability (Table 1; p < 0.05). Overall, the rRmLTI vac-
ine afforded 32% immunoprotection against cattle tick infestation
Table 1).
ig. 2. Proﬁle of humoral immune response in cattle vaccinated with rRmLTI.
bsorbance  readings are for ELISA tests of weekly antisera samples collected from
wo groups of six cattle immunized at 0, 15, and 30 days (arrows) with rRmLTI
squared  line) or adjuvant (triangled line). Tick icon indicates day 51 after the ﬁrst
accination, which is when cattle were infested. Antibody titers of immunized cattle
re depicted as the OD490 nm value of the 1:100 dilution of serum samples. Individ-
al  samples in each group collected on the day shown in the ﬁgure were pooled for
LISA testing.
ig. 3. Reduced weight of female R. microplus ticks feeding on cattle vaccinated
ith  rRmLTI. *Group means ± SD are shown. Collection day with asterisk indicates
he  average weight between engorged female ticks feeding on vaccinated or control
attle was  signiﬁcantly different (p < 0.05). shown.
adult female ticks; DW,  tick weight; DO, egg laying capacity; DF, fertility. Efﬁcacy
s, CRO: reduction in the egg laying capacity, CRF: reduction in fertility.
3.3. Effect of puriﬁed anti-rRmLTI IgG on tick egg eclosion
The effect of the anti-rRmLTI antibody response on egg hatch-
ing was  explored further ex vivo. An inverse dose-response was
observed between egg hatching and the amount of IgG imbibed by
the gravid tick (Fig. 5). The viability of eggs laid by female ticks
ingesting IgG antibodies from cattle vaccinated with rRmLTI was
signiﬁcantly compromised and hatching decreased 75.6% in eggs
from ticks fed 100 g of IgG (p < 0.05).
Fig. 4. Percent hatch of eggs laid by female R. microplus ticks feeding on control
cattle  or those vaccinated with rRmLTI. Refer to text for details on egg processing.
Fig. 5. Anti-rRmLTI IgG imbibed by female cattle ticks inhibits egg hatching in a
dose-dependent manner. *Four groups of ten ticks received 0, 25, 50 and 100 g of
puriﬁed IgG. Each tick was  fed the speciﬁed amount of IgG in a volume of 20 L using
a capillary tube. Treatment means ± SD are shown. Mean percent hatch inhibition
was  signiﬁcantly different between the treatment groups.
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Lig. 6. Alignment of predicted amino acid sequences for rRmLTI, EST CK186726, Bm
mTI-D, BmTI-2, and BmTI-3.
.4. Identiﬁcation of RmLTI as a member of the Kunitz-bovine
ancreatic trypsin inhibitor family
A comparison of the DNA sequences from the EST CK186726 and
he RmLTI clone optimized for codon usage in P. pastoris revealed
7% identity between the two sequences. The RmLTI DNA sequence
n the yeast expression system was missing nineteen bases of the
orresponding EST sequence (data not shown).
Fig. 6 depicts the alignment of predicted amino acid sequences
or rRmLTI, EST CK186726, BmTI-6 from ovarian cDNA, and N-
erminal amino acid sequence information for BmTI-A, BmTI-D,
mTI-2, and BmTI-3. The deduced amino acid sequences between
RmLTI, EST CK186726, and BmTI-6 are 99% identical. Nucleic
cid sequence coding for six additional amino acids (EAEAEF) in
he N-terminus, and thirty two amino acids (VPRAAAAASFLEQK-
ISEEDLNSAVDHHHHHH) in the C-terminal portion of the putativefrom ovarian cDNA, and N-terminal amino acid sequence information for BmTI-A,
rRmLTI  product was  added during cloning procedures to allow
insertion of a restriction site and coding sequence for the poly-His
peptide.
The similarity between their partial amino acid sequences sug-
gested that RmLTI in larvae is a member of the Kunitz-bovine
pancreatic trypsin inhibitor (BPTI) family like BmTI-6 in the ovary
of adult female cattle ticks. Further exploration of the putative
function of RmLTI is reﬂected in Fig. 7. Relevant protein signature
features identiﬁed in the deduced amino acid sequence encoded
in the expressed sequence tag CK186726 include three putative
Kunitz-BPTI domains and two  putative Kunitz proteinase inhibitor
I2 conserved sites. As noted in BmTI-6, six N-glycosylation sites
were present in the partial protein sequence of RmLTI. Six cysteine
residues were observed within each of the three Kunitz domains,
which are thought to form disulﬁde linkages contributing stability
to the compact polypeptide in its folded form.
R. Andreotti et al. / Vaccine 30 (2012) 6678– 6685 6683
Fig. 7. A trypsin inhibitor in R. microplus larvae is encoded in expressed sequence tag CK186726. The amino acid sequence deduced from the RmLTI DNA clone optimized
f can in
w (C) pr
p ibitor 
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dor use in P. pastoris was  scanned for protein signature features using the InterProS
ith asterisks. A dotted line underlines Asn-Xaa-Ser/Thr codons. Cysteine residues 
utative Kunitz-BPTI domains are underlined. Two  predicted Kunitz proteinase inh
. Discussion
Assessment of the efﬁcacy against cattle tick infestation in
ovines using a vaccine containing the recombinant form of a mem-
er of the Kunitz-BPTI family from R. microplus produced in the
. pastoris expression system is reported for the ﬁrst time here. A
peciﬁc and robust humoral immune response against rRmLTI was
chieved with the vaccination protocol consisting of three immun-
zations, each applied every two weeks. The 32% efﬁcacy obtained
ith the rRmLTI formulation reﬂects the signiﬁcant challenge of
iscovering highly efﬁcacious antigens protecting cattle against R.formatics tool. Asparagine residues (N) predicted to be N-glycosylated are marked
edicted to form disulﬁde bonds are highlighted in gray. Amino acids encompassing
I2 conserved sites are double-underlined.
microplus infestation. Vaccination experiments where Bos indicus
cattle were immunized with a mixture of puriﬁed larval trypsin
inhibitors containing one or two Kunitz-type domains afforded
72.8% efﬁcacy against R. microplus infestation [22]. In contrast, the
level of immunoprotection obtained in crossbred cattle vaccinated
with the synthetic polypeptide containing 29 aa residues derived
from the N terminus of the R. microplus trypsin inhibitor A was
18.4% [23]. As the gene encoding RmLTI remains to be fully charac-
terized, the apparent discrepancy between speciﬁc antibody levels
and the low level of efﬁcacy obtained with the rRmLTI vaccine may
be due to the partial gene sequence of the EST used to produce
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he recombinant protein product in the yeast expression system.
lternatively, the structural and functional redundancy in proteins
elonging to the Kunitz family present in R. microplus may  also
ccount for the relatively low efﬁcacy attained with the rRmLTI
accine.
Although binding of rRmLTI by polyclonal antibodies from mice
mmunized with tick larva extract indicates that the recombinant
olypeptide produced in P. pastoris was as antigenic as the native
orm of the cognate larval trypsin inhibitor, it is possible that
hose antibodies recognized epitopes shared by the several trypsin
nhibitors discovered in R. microplus larvae. Antiserum from cattle
accinated with puriﬁed R. microplus trypsin inhibitors recognized
BmTI-6 produced in P. pastoris [21]. Antigenic similarity appar-
ntly extends beyond intra-speciﬁc boundaries because antiserum
gainst the native form of R. microplus larval trypsin inhibitors
ross-reacts with trypsin inhibitors identiﬁed in R. sanguineus lar-
ae [27]. Immunogenicity of the rRmLTI is reﬂected in the kinetics
f the bovine humoral immune response. The signiﬁcant effect on
he rate of larvae hatching from eggs laid by female ticks para-
itizing vaccinated cattle, which was ampliﬁed by feeding female
icks with puriﬁed anti-rRmLTI IgG suggests that potentiation of the
umoral response, perhaps using other adjuvants, could enhance
he efﬁcacy of a polyvalent vaccine with Kunitz inhibitors from
. microplus. Adjuvant choice was shown to inﬂuence antibody
evels, which correlated with the level of inhibition on malaria para-
ites [28]. However, no direct correlation was observed between
ntibodies against rRmLTI and overall efﬁcacy in our study. By
omparison, the vast array of Kunitz type inhibitors present in
. microplus was invoked to explain the apparently small impact
ilencing the gene coding for boophilin, a double Kunitz type
hrombin inhibitor expressed in the gut, had on egg production
29].
Considering the purported involvement of larval trypsin
nhibitors and conﬁrmed role of other Kunitz inhibitors in blood
eeding, the reduced number of female ticks detaching from
accinated cattle may  reﬂect the impact of bovine anti-rRmLTI anti-
odies on the ability of R. microplus to acquire a blood meal [20,29].
owever, the physiological roles of RmLTI and BmTI-6 remain to be
etermined in the larval and adult stages of the cattle tick, respec-
ively, despite similarities in their partial nucleotide and amino acid
equences. Without knowing the function of RmLTI and BmTI-6,
t remains possible that the decrease in hatching rates observed
n eggs laid by female ticks fed puriﬁed IgG antibodies obtained
rom vaccinated cattle resulted from the effects of antibody bind-
ng to epitopes shared by rRmLTI and the native form of BmTI-6 in
. microplus ovaries.
The  Kunitz family of polypeptides is one of at least 20 fami-
ies belonging to the canonical type of serine protease inhibitors
30]. A characteristic of proteins belonging to this family is the
unitz domain that can be present in single or multiple copies.
t least 303 Kunitz proteins have been identiﬁed in ticks thus far
nd some of them can contain as many as seven Kunitz domains
31]. Cysteine patterns were used to classify Kunitz proteins into
hree groups to facilitate study of their evolution in the Lyme dis-
ase vector Ixodes scapularis and to expand the analysis to ticks in
eneral [31]. Although primarily involved in proteinase inhibition,
he Kunitz domain has evolved to perform other functions requir-
ng protein-protein interactions [32]. Cattle tick ovaries, fat body,
emocytes, and midgut contain Kunitz proteins [21,29,33,34]. Pro-
eomic studies revealed the presence of Kunitz proteins that are
p-regulated in ovarian tissue when R. microplus is infected with
abesia bovis [35]. A publicly available genomic database called Cat-
leTickBase offers the opportunity to study the evolutionary history
f Kunitz proteins in R. microplus [35]. It is possible that BmTI-6 and
he RmLTI encoded by CK186726 are splice variants of the same
ene or paralogs of the same Kunitz protein as suggested before0 (2012) 6678– 6685
for  BmTI-A and other Kunitz proteins present in cattle tick ovary
[34].
Previous research documenting 72.8% efﬁcacy against R.
microplus infestation using puriﬁed trypsin inhibitors and the
critical role Kunitz proteins play in various biological processes
including proteinase inhibition warrant continued vaccine discov-
ery research with this protein family. Production of rRmLTI in P.
pastoris facilitates its use to formulate polyvalent cattle tick vac-
cines that include other Kunitz proteins or different antigens from
R. microplus. The level of immunoprotection attained through vac-
cination with rRmLTI was low as compared to other novel antigens
discovered recently [37,43]. Of note are the results from vaccina-
tion using immunogenic peptides that yielded tick efﬁcacy between
80 and 90% [44,45]. Salivary glands, midgut, and ovaries are prime
targets to disrupt cattle tick biology using vaccines and Kunitz pro-
teins are abundant in those tissues. The use of epitopes from Kunitz
proteins in combination with immunogenic portions of other tick
molecules to produce a dual action vaccine could be another way  to
exploit the redundancy of R. microplus Kunitz inhibitors to innovate
a highly efﬁcacious cattle tick vaccine.
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